First-line herceptin® monotherapy in metastatic breast cancer

Oncology

Volumn 61, Issue SUPPL. 2, 2001, Pages 37-42

  Vogel, Charles L ^a,i   Cobleigh, Melody A ^b   Tripathy, Debu ^c   Gutheil, John C ^d   Harris, Lyndsay N ^e   Fehrenbacher, Louis ^f   Slamon, Dennis J ^g   Murphy, Maureen ^h   Novotny, William F ^h   Burchmore, Michael ^h   Shak, Steven ^h   Stewart, Stanford J ^h  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VICAL INC   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Kaiser Permanante   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h GENENTECH INC   (United States)

ⁱ Southpoint Medical Center   (United States)

Author keywords

First line therapy; FISH; HER2 positive; Herceptin ; IHC 3+; Metastatic breast cancer; Monotherapy

Indexed keywords

TRASTUZUMAB;

ASTHENIA; BREAST CARCINOMA; CANCER INCIDENCE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG TOLERANCE; DYSPNEA; FEVER; HEADACHE; HUMAN; METASTASIS; MONOTHERAPY; NAUSEA; PAIN; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FEVER; HEART DISEASES; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PAIN; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SAFETY; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 17944379907     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055400     Document Type: Conference Paper

References (25)

1. HER2monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
2. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
3. Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials
4. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
5. Humanization of an anti-p185HER2 antibody for human cancer therapy
6. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
7. Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer
8. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
9. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
10. Cardiotoxicity in patients receiving Trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveilance artifact?
11. Treatment of breast cancer
12. HER2 causes transformation and tumorigenesis of NIH 3T3 cells
13. Cancer statistics, 1999
14. HER2 monoclonal antibodies
15. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
16. Overall survival (OS) advantage to simultaneous chemotherapy (Crx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
17. Health related quality of life (HRQL) of patients with first-line, single-agent, Trastuzumab (Herceptin) for metastatic HER-2 overexpressing breast cancer
18. Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells
19. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
20. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neumonoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
21. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
22. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
23. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
24. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
25. First-line, non-hormonal, treatment of woman with HER2 overexpressing metastatic breast cancer with Herceptin (Trastuzumab, humanized anti-HER2 antibody)